Onward® medical reaffirms 2024 strategic priorities and releases unaudited q2 financial highlights

Company expects to commercialize the investigational arc-ex ® system in q4 2024 and has commenced launch preparations company preparing to initiate global pivotal trial for investigational arc-im ® therapy to address blood pressure instability after spinal cord injury company expects to advance clinical and development activities for its unique arc-bci ™ brain-computer interface therapy eindhoven, the netherlands, aug. 05, 2024 (globe newswire) -- onward medical n.v. (euronext: onwd), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (sci), today reaffirms its 2024 strategic priorities and releases its unaudited q2 financial highlights.
ARC Ratings Summary
ARC Quant Ranking